Bionic Vision Technologies (BVT) has announced that Ash Attia has been named Chief Executive Officer (CEO), effective July 22.
This appointment rounds comes shortly after the appointment of Brian Gordon as Chief Scientific Officer (CSO) and Dr. Adrian Oates as Chief Operating Officer (COO).
Mr. Attia has over 30 years of senior executive management experience in implantable devices and biotechnology. Most recently, Mr. Attia held the position of Vice President Asia Pacific, the Middle East and Israel, at TransMedics Inc. Prior to this, Mr. Attia held Vice President and Managing Director roles within several other major Australian and International medtech organizations such as Thoratec, St. Jude Medical, Micromed, Syncardia, Ventracor, Biotronik, SulzerMedica and Telectronics.
Mr. Attia has extensive experience in medical technology commercialization, general management, research and development, marketing, market entry strategies, regulatory and reimbursement across multiple geographies (USA, Asia Pacific and Europe). He is a Fellow of the Australian Institute of Company Directors and has extensive governance experience being a Non- Executive Director of ASX-listed Company DorsaVi for over 10 years.